Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Mimedx Group Inc (MDXG)
Mimedx Group Inc (MDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Mimedx Group Inc 1775 W OAK COMMONS COURT NE MARIETTA GA 30062 USA

www.mimedx.com P: 770-651-9100

Description:

MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.

Key Statistics

Overview:

Market Capitalization, $K 954,291
Enterprise Value, $K 980,831
Shares Outstanding, K 116,377
Annual Sales, $ 267,840 K
Annual Net Income, $ -30,200 K
Last Quarter Sales, $ 81,710 K
Last Quarter Net Income, $ 8,530 K
EBIT, $ 12,050 K
EBITDA, $ 16,560 K
60-Month Beta 1.36
% of Insider Shareholders 19.90%
% of Institutional Shareholders 43.85%
Float, K 93,218
% Float 80.10%
Short Volume Ratio 0.55

Growth:

1-Year Return 70.75%
3-Year Return 55.01%
5-Year Return 431.17%
5-Year Revenue Growth -16.60%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.05 on 10/30/23
Latest Earnings Date 02/28/24
Earnings Per Share ttm -0.03
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 155.56%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/13/21

MDXG Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 24.53
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -0.72%
Profit Margin % -11.28%
Debt/Equity 0.00
Price/Sales 3.05
Price/Cash Flow N/A
Price/Book 722.76
Book Value/Share 0.01
Interest Coverage -4.97
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar